Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It contains specific transaction data for a single event:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Price: £16.6781 per share.
- Volume: 1.924 shares.
- Date: July 14, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing reports an initial notification of a share acquisition by Dr. M M Slaoui, Chairman of Global Vaccines. There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is strictly a regulatory disclosure of a specific insider transaction.
Investor Verification Points
- Verify the identity of the PDMR: Dr. M M Slaoui (Chairman, Global Vaccines).
- Confirm the transaction was an acquisition via dividend re-investment on July 14, 2016.
- Note the transaction volume is minimal (1.924 shares) and does not indicate a significant change in ownership structure.
- Recognize that this filing does not contain quarterly or annual financial performance data.